These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 18452071)

  • 1. Cardiac involvement with mycosis fungoides: could this explain alemtuzumab toxicity?
    Sleigh KA; Smith ME; Rule SA
    Leuk Lymphoma; 2008 Oct; 49(10):2022-4. PubMed ID: 18452071
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
    Lenihan DJ; Alencar AJ; Yang D; Kurzrock R; Keating MJ; Duvic M
    Blood; 2004 Aug; 104(3):655-8. PubMed ID: 15073032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome.
    Lundin J; Kennedy B; Dearden C; Dyer MJ; Osterborg A
    Blood; 2005 May; 105(10):4148-9. PubMed ID: 15867423
    [No Abstract]   [Full Text] [Related]  

  • 4. Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy.
    Bolli N; Di Ianni M; Simonetti S; Cerroni L; Liso A; Falini B; Tabilio A
    Lancet Oncol; 2004 Jan; 5(1):64-5. PubMed ID: 14700612
    [No Abstract]   [Full Text] [Related]  

  • 5. Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab.
    Weder P; Anliker M; Itin P; Bargetzi M
    Dermatology; 2004; 208(3):281-3. PubMed ID: 15118391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe cardiac toxicity after monoclonal antibody therapy.
    Damaj G; Rubio MT; Audard V; Hermine O
    Eur J Haematol; 2002 May; 68(5):324. PubMed ID: 12144543
    [No Abstract]   [Full Text] [Related]  

  • 7. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.
    Querfeld C; Mehta N; Rosen ST; Guitart J; Rademaker A; Gerami P; Kuzel TM
    Leuk Lymphoma; 2009 Dec; 50(12):1969-76. PubMed ID: 19860617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome.
    Lundin J; Hagberg H; Repp R; Cavallin-Ståhl E; Fredén S; Juliusson G; Rosenblad E; Tjønnfjord G; Wiklund T; Osterborg A
    Blood; 2003 Jun; 101(11):4267-72. PubMed ID: 12543862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab.
    Kennedy GA; Seymour JF; Wolf M; Januszewicz H; Davison J; McCormack C; Ryan G; Prince HM
    Eur J Haematol; 2003 Oct; 71(4):250-6. PubMed ID: 12950233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment.
    Capalbo S; Delia M; Dargenio M; Liso A; Diomede D; Garofalo L; Liso V
    Med Oncol; 2003; 20(4):389-96. PubMed ID: 14716037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy.
    Postorino M; Pupo L; Provenzano I; Del Principe MI; Buccisano F; Franceschini L; Rizzo M; Nasso D; Meconi F; Onnis I; Vaccarini S; Zizzari A; Anemona L; Mauramati S; Bruno E; Cantonetti M; Amadori S
    Ann Hematol; 2016 Jan; 95(1):153-154. PubMed ID: 26442854
    [No Abstract]   [Full Text] [Related]  

  • 12. Alemtuzumab induced complete remission of romidepsin-refractory large cell transformation of mycosis fungoides.
    Kwong YL
    Ann Hematol; 2014 Apr; 93(4):713-4. PubMed ID: 23934231
    [No Abstract]   [Full Text] [Related]  

  • 13. The development of sarcoidosis with the use of alemtuzumab - clues to T-cell immune reconstitution.
    Thachil J; Jadhav V; Gautam M; McKew S; Arumainathan A; Collins D; Smyth C; Harper J; Pettitt A
    Br J Haematol; 2007 Aug; 138(4):559-60. PubMed ID: 17587337
    [No Abstract]   [Full Text] [Related]  

  • 14. Ventricular tachycardia revealing cardiac infiltration by mycosis fungoides.
    Carrilho-Ferreira P; Ferreira M; Ferreira C; Correia MJ; Nunes Diogo A; Brás Rosário L
    Rev Port Cardiol; 2014; 33(7-8):481-2. PubMed ID: 25155002
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical, histological and immunohistochemical study of the early diagnosis of mycosis fungoides].
    Goos M; Eckstein M; Biskup K
    Z Hautkr; 1983 Mar; 58(6):373-84. PubMed ID: 6845804
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunophenotypic stability of Sézary cells by flow cytometry: usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy.
    Vaughan J; Harrington AM; Hari PN; Kroft SH; Olteanu H
    Am J Clin Pathol; 2012 Mar; 137(3):403-11. PubMed ID: 22338052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab in clinical practice: a British Columbia experience.
    Hui D; Lam W; Toze C; Delorme M; Noble M; Klimo P; Sutherland J; Gill K; Connors J; Sehn L
    Leuk Lymphoma; 2008 Feb; 49(2):218-26. PubMed ID: 18231907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rediscovering alemtuzumab: current and emerging therapeutic roles.
    Gribben JG; Hallek M
    Br J Haematol; 2009 Mar; 144(6):818-31. PubMed ID: 19183194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab in Sézary syndrome: efficient but not innocent.
    Ure UB; Ar MC; Salihoglu A; Guner SI; Baran A; Oguz O; Ferhanoglu B
    Eur J Dermatol; 2007; 17(6):525-9. PubMed ID: 17951134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of alemtuzumab in the treatment of chronic lymphocytic leukemia.
    Zent CS
    Leuk Lymphoma; 2008 Feb; 49(2):175-6. PubMed ID: 18231900
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.